Q1 2026 · 13F-HR
Palo Alto Investors LPholdings as filed
Filed 2026-05-15 · accession 0001306923-26-000004
$653.9M
Reported value
51
Positions
2026-03-31
Period end
The Brief · Palo Alto Investors LP · Q1 2026
AI · grounded in 13F
Palo Alto Investors LP closed its position in Gossamer Bio Inc GOSS, reducing its exposure by $13.86M. The fund established a new position in Celldex Therapeutics Inc CLDX worth $9.4M. Additionally, the manager increased its holdings in Mirum Pharmaceuticals Inc MIRM by 107.88% and Bicara Therapeutics Inc BCAX by 84.35%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $67.9M | 10.4% | 415,269 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $63.9M | 9.78% | 2,872,695 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $62.8M | 9.60% | 921,607 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $38.7M | 5.92% | 685,182 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $37.2M | 5.70% | 62,809 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $35.4M | 5.41% | 638,161 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $30.0M | 4.59% | 325,175 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $30.0M | 4.58% | 1,652,972 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $25.8M | 3.95% | 140,719 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $25.7M | 3.93% | 401,719 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $22.3M | 3.41% | 6,349,563 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $20.2M | 3.09% | 864,986 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $16.3M | 2.50% | 2,948,090 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $16.1M | 2.46% | 1,113,045 | Common | SOLE |
| G6674U108 | NVCR | NOVOCURE LTD | $14.0M | 2.13% | 1,280,439 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $12.5M | 1.91% | 596,495 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $11.7M | 1.80% | 1,208,568 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $10.9M | 1.67% | 550,408 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $9.4M | 1.44% | 296,408 | Common | SOLE |
| 14167L103 | CDNA | CAREDX INC | $9.2M | 1.41% | 531,870 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $8.6M | 1.31% | 242,560 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $8.0M | 1.23% | 1,514,504 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $7.2M | 1.11% | 213,601 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $7.1M | 1.09% | 41,520 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $7.0M | 1.07% | 229,763 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $6.8M | 1.05% | 230,453 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $6.2M | 0.95% | 1,391,382 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $6.1M | 0.93% | 1,613,430 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $4.5M | 0.69% | 234,582 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $3.0M | 0.46% | 51,345 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $2.9M | 0.45% | 59,985 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $2.8M | 0.42% | 84,631 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $2.7M | 0.41% | 33,640 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $2.4M | 0.37% | 18,117 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $2.2M | 0.33% | 508,846 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $2.1M | 0.32% | 32,195 | Common | SOLE |
| 28238P109 | EHTH | EHEALTH INC | $1.9M | 0.29% | 1,482,797 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $1.9M | 0.29% | 39,605 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE-ADR | $1.7M | 0.27% | 19,614 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $1.5M | 0.23% | 1,010,510 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $1.3M | 0.20% | 246,093 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC-ADR | $936,770 | 0.14% | 201,890 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $935,441 | 0.14% | 1,787 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $690,959 | 0.11% | 3,985 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC ADR | $639,356 | 0.10% | 115,616 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $605,578 | 0.09% | 104,410 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $487,715 | 0.07% | 108,865 | Common | SOLE |
| 457730109 | INSP | INSPIRE MEDICAL SYSTEMS INC | $452,460 | 0.07% | 8,772 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $440,510 | 0.07% | 24,500 | Common | SOLE |
| N71542109 | PRQR | PROQR THERAPEUTICS NV | $305,867 | 0.05% | 188,807 | Common | SOLE |
| 01438T106 | ALDX | ALDEYRA THERAPEUTICS INC | $263,148 | 0.04% | 155,709 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.